Added 50k today |
Oh dear !
Mr bird brain not very happy
Share price heading towards 7.5p to 8p |
On support MA, next one is 9.5pI will buy another 100k if it goes below 10pL2 just weakened so keeping an eye on this to buy on weakness |
Is this the path into Saudi via MölnlyckeMölnlycke Care celebrates a new chapter in healthcare in the Kingdom of Saudi Arabiahttps://news.cision.com/molnlycke/r/tamer-molnlycke-care-celebrates-a-new-chapter-in-healthcare-in-the-kingdom-of-saudi-arabia,c4111334 |
Hoping this is the new floor nowBring on the FDA approval |
 26 February 2025 ONDINE BIOMEDICAL INC.
Ondine Biomedical Strengthens Leadership Team with the Appointment of Michael Behlke as non-Board CFO & COO
Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial treatments, is pleased to announce the appointment of Michael S. Behlke as Chief Financial Officer (CFO) and Chief Operating Officer (COO), effective immediately. Recognized in the US MedTech community for his career achievements, Mr. Behlke brings over 30 years of financial and operational leadership experience, positioning Ondine for accelerated growth and commercialization success.
Mr. Behlke's distinguished career includes securing over $250 million in funding, supporting acquisitions exceeding $700 million, and driving commercialization strategies for emerging and mid-stage medical companies. Prior to joining Ondine, he served as CFO and Acting COO at Ventec Life Systems with full P&L responsibility, where he played a critical role in scaling the company's revenue from $13 million to $500 million annually and in its landmark partnership with General Motors to rapidly scale up and manufacture ventilators for the US Strategic National Stockpile during the COVID-19 pandemic.
Carolyn Cross, Ondine's Chief Executive Officer:
"We are thrilled to welcome Michael to our leadership team. Ondine is at a critical inflection point as we expand our hospital-based infection prevention solutions. Michael's extensive MedTech industry experience, operational leadership, and business transformation successes will be key to accelerating our worldwide commercialization efforts, initially within Canada and the UK/EU, and then rapidly expanding into the U.S. post-FDA approval."
In his new role, Mr. Behlke will oversee Ondine's capital markets strategies, operational efficiency, and international expansion, ensuring the company's is well-positioned for sustained growth and market leadership. His deep expertise in P&L management, business transformation, and supply chain execution will be key to advancing Ondine's mission of revolutionizing infection prevention through its photodisinfection-based platform technology.
Michael Behlke, CFO & COO of Ondine Biomedical:
"I am honored to join Ondine at this pivotal moment. The company's groundbreaking photodisinfection technology represents a paradigm shift in infection control. I look forward to working with this talented team to drive operational excellence, financial growth, and global adoption of this life-saving technology."
This appointment strengthens Ondine's leadership team and underscores the Company's commitment to expanding its footprint in key global markets and addressing the urgent need for innovative antimicrobial solutions in healthcare settings. |
Another research article on this https://dataintelo.com/report/global-mupirocin-ointment-market/amp |
Totally agree , need to build distribution channels with more partnerships Did some more research on this Since Ondine are targeting Muciprion Msrket Which uses ointments , creams and othersI found some data on just the ointment usage The global topical mupirocin ointment market is expected to grow significantly, with a market value projected to reach USD 1.5 billion by 2028. The compound annual growth rate (CAGR) for the market is anticipated to be 6.3% during the forecast period of 2023-2028.Which regions are leading the Topical Mupirocin Ointment Market?* North America (United States, Canada and Mexico)* Europe (Germany, UK, France, Italy, Russia and Turkey etc.)* Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)* South America (Brazil, Argentina, Columbia etc.)* Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)Who is the largest Manufacturers of Topical Mupirocin Ointment Market worldwide?Glaxosmithkline, Glenmark Pharms, Hainan Quanxing Pharmaceutical, Hanzhou Zhuyangxin Pharmaceutical, Humanwell Healthcare, Jiuzheng Pharm, Perrigo, Sandoz, SmithKline & French, Sun Pharma, Taro Pharmaceutical, Teva |
He now pretends he's filtered me |
Mr beeks read his post from the FAR thread
jailbird20 Feb '25 - 07:38 - 872 of 876
0 0 1
Zico
How is GDR doing after watching OBI rise 50%?
You sure pick 'em |
I don't hold here at the moment, but what benefit do you get Z1co from posting such tripe? |
Will fall to around 9p |
Hardly any revenue , losses this year will again exceed £15m.
Shares are too expensive |
Mr bird brain lol!
You can run but you can't hide.
The idiot calls me out and is now behaving like a clown |
ZIco,
You are on my filtered list , so I refuse to read your comments.
Please do not follow me around, I am not interested. |
Oh dear share price is heading sub 10p again
Come on Mr bird brain get ramping
:) |
I just used a google AI search and the numbers come up even higher Cost of SSIs SSIs are a significant healthcare burden, resulting in: Increased hospital stays, Additional medical treatments, and Lost productivity. The estimated annual cost of SSIs in the United States is between $3.5 billion and $10 billion. |
This is from CDC website itself
hxxps://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf
Data is a few years outdated in first last paragraph
But even so the biggest thing from this is the annual cost of SSIs in the last paragraph, so current numbers will be higher post COVID
“SSI is the most costly HAI type with an estimated annual cost of $3.3 billion,”!!!!!
If Steriwave replaces Muciprion , this could be a big % of the $3.3 billion. So just do the numbers
If we use a extremely conservative number , say just 10% would be $300 million a year from just USA alone
globally numbers be higher
The CDC healthcare-associated infection (HAI) prevalence survey found that there were an estimated 110,800 surgical site infections (SSIs) associated with inpatient surgeries in 2015
.
Based on the 2023 HAI data results published in the NHSN’s HAI Progress Report, about a 2%
increase in the SSI standardized infection ratio (SIR) related to all NHSN operative procedure categories combined compared to the previous year2. In addition, the 2023 HAI data found a 3% significant increase in SIR related to the Surgical Care Improvement Project (SCIP) NHSN operative procedure categories compared to the previous year2. Additional SSI HAI data can be found in the annual HAI Progress Report2
.
While advances have been made in infection control practices, including improved operating room ventilation, sterilization methods, barriers, surgical technique, and availability of
CDC 9 - 1January 2025 Procedure-associated Module
SSI Events antimicrobial prophylaxis, SSIs remain a substantial cause of morbidity, prolonged hospitalization, and mortality. It is reported, SSI accounts for 20% of all HAIs and is associated to a 2-to 11-fold increase in the risk of mortality with 75% of SSI-associated deaths directly attributable to the SSI3,4. SSI is the most costly HAI type with an estimated annual cost of $3.3
billion, and extends hospital length of stay by 9.7 days, with cost of hospitalization increased by
more than $20,000 per admission |
bamboo,
Thanks a good point, there must be a reason the company is put this out today. |
jb, thanks for posting.
I guess that given the regime change, the US would require a US based partnership for distribution. |
This company is still under the radar |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
